Callitas Health (Callitas Health) EBIT : $-0.47 Mil (TTM As of Sep. 2020)

View and export this data going back to 2008. Start your Free Trial

What is Callitas Health EBIT?

Callitas Health's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2020 was $-0.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2020 was $-0.47 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Callitas Health's annualized ROC % for the quarter that ended in Sep. 2020 was -35.17%. Callitas Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Callitas Health EBIT Historical Data

The historical data trend for Callitas Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Callitas Health EBIT Chart

Callitas Health Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EBIT

Get a 7-Day Free Trial

-2.90

-1.47

-6.30

-3.97

-1.21

Callitas Health Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
EBIT	Get a 7-Day Free Trial															-0.11	-0.18	-0.07	-0.14	-0.09

Competitive Comparison of Callitas Health's EBIT

For the Biotechnology subindustry, Callitas Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Callitas Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Callitas Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Callitas Health's EV-to-EBIT falls into.

Callitas Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.

Callitas Health (OTCPK:MPHMF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Callitas Health's annualized ROC % for the quarter that ended in Sep. 2020 is calculated as:

	ROC % (Q: Sep. 2020 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2020 )	+	Invested Capital (Q: Sep. 2020 ))	/ count )
=	-0.488 * ( 1 - 0% )	/	( (1.334	+	1.441)	/ 2 )
=	-0.488	/	1.3875
=	-35.17 %

where

	Invested Capital		(Q: Jun. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.125	-	2.235	-	( 0.057	-	max(0, 3.569	-	0.125	+	0.057	))
=	1.334

	Invested Capital		(Q: Sep. 2020 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.103	-	2.285	-	( 0.017	-	max(0, 3.726	-	0.103	+	0.017	))
=	1.441

Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Callitas Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2020 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2020		Q: Sep. 2020
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.352	/	( ( (0 + max(-2.77, 0))	+	(0 + max(-2.803, 0)) )	/	2 )
=	-0.352	/	( ( 0	+	0 )	/	2 )
=	-0.352	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.067	+	0.001)	-	(2.235	+	0.066	+	0.537)
=	-2.77

	Working Capital		(Q: Sep. 2020 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.086	+	0)	-	(2.285	+	0.049	+	0.555)
=	-2.803

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Callitas Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2020 )
	=	-0.472	/	0.000
	=	%

Callitas Health EBIT Related Terms

Thank you for viewing the detailed overview of Callitas Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Callitas Health (Callitas Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Callitas Health Inc (OTCPK:MPHMF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

734 - 1055 Dunsmuir Street, Vancouver, BC, CAN, V7X 1B1

Website

http://www.callitas.com

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.